This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwarz, P. Articles by Dannaoui, E. Search for Related Content PubMed PubMed Citation Articles by Schwarz, P. Articles by Dannaoui, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2006, p. 113-120, Vol. 50, No. 1
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.1.113-120.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Efficacy of Amphotericin B in Combination with Flucytosine against Flucytosine-Susceptible or Flucytosine-Resistant Isolates of Cryptococcus neoformans during Disseminated Murine Cryptococcosis

Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moléculaire, CNRS FRE2849, Institut Pasteur, 75724 Paris Cedex 15, France,¹ Université Paris Descartes, Faculté de Médecine, AP-HP, Hôpital Necker-Enfants-Malades, Service des Maladies Infectieuses et Tropicales, 75743 Paris Cedex 15, France,² Université Paris Descartes, Faculté de Médecine, AP-HP, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie, 75015 Paris, France³

Received 20 June 2005/ Returned for modification 28 August 2005/ Accepted 11 October 2005

Whether or not flucytosine should be administered to patients infected with Cryptococcus neoformans isolates found to be resistant to flucytosine in vitro remains a controversial issue. Thus, the efficacy of amphotericin B and flucytosine in combination was investigated by mortality and fungal burden studies in a murine model of disseminated cryptococcosis using two clinical isolates of Cryptococcus neoformans, one susceptible and one resistant (i.e., 64 µg/ml) to flucytosine. Amphotericin B was given intraperitoneally at 0.25 or 0.5 mg/kg/day, while flucytosine was given at 100 or 250 mg/kg/day orally. Treatment was started 24 h or day 6 after inoculation and continued for 5 days in fungal burden and mortality studies, respectively. The combination of amphotericin B at 0.5 mg/kg/day and flucytosine at 250 mg/kg/day was significantly more effective than monotherapies for reducing fungal burden in brain, spleen, and lungs after infection by the flucytosine-susceptible isolate and in brain and spleen for the flucytosine-resistant isolate. For the flucytosine-resistant isolate, the combination of amphotericin B at 0.5 mg/kg/day with flucytosine at 100 mg/kg/day was significantly better than monotherapies for reducing the fungal burden in the brain. Survival obtained after the combination of amphotericin B at 0.5 mg/kg/day and flucytosine at 250 mg/kg/day increased compared to that obtained with monotherapies for both isolates, but the difference was statistically significant only for the flucytosine-susceptible isolate. Antagonism was never observed. This study demonstrates the beneficial effect of the addition of flucytosine to amphotericin B against experimental disseminated cryptococcal infection even when the C. neoformans isolate is resistant to flucytosine.

This article has been cited by other articles:

• Paluszynski, J. P., Klassen, R., Meinhardt, F. (2008). Genetic prerequisites for additive or synergistic actions of 5-fluorocytosine and fluconazole in baker's yeast. Microbiology 154: 3154-3164 [Abstract] [Full Text]  
• Brouwer, A. E., van Kan, H. J. M., Johnson, E., Rajanuwong, A., Teparrukkul, P., Wuthiekanun, V., Chierakul, W., Day, N., Harrison, T. S. (2007). Oral versus Intravenous Flucytosine in Patients with Human Immunodeficiency Virus-Associated Cryptococcal Meningitis. Antimicrob. Agents Chemother. 51: 1038-1042 [Abstract] [Full Text]  
• Schwarz, P., Janbon, G., Dromer, F., Lortholary, O., Dannaoui, E. (2007). Combination of Amphotericin B with Flucytosine Is Active In Vitro against Flucytosine-Resistant Isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 51: 383-385 [Abstract] [Full Text]  
• Dias, A. L. T., Matsumoto, F. E., Melhem, M. S. C., da Silva, E. G., Auler, M. E., de Siqueira, A. M., Paula, C. R. (2006). Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates.. J Med Microbiol 55: 1693-1699 [Abstract] [Full Text]  
• Dannaoui, E., Abdul, M., Arpin, M., Michel-Nguyen, A., Piens, M. A., Favel, A., Lortholary, O., Dromer, F., the French Cryptococcosis Study Group, (2006). Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.. Antimicrob. Agents Chemother. 50: 2464-2470 [Abstract] [Full Text]